Mylan announced the launch of its generic Brevibloc injection in single-dose bags on September 13. This is the first generic version of Baxter International’s (BAX) Brevibloc. The ready-to-use esmolol hydrochloride in a sodium chloride injection is available as a 2,500 mg/250 mL (10 mg/mL) single-dose plastic bag and a 2,000 mg/100 mL (20 mg/mL) single-dose plastic bag.
According to Mylan, this injection is indicated for the “short-term treatment of control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia and control of perioperative tachycardia and hypertension.”
According to IQVIA, Brevibloc had sales of $126.0 million in the United States for the 12 months ended June 30.
Mylan’s cardiovascular portfolio
Mylan (MYL) has a huge portfolio of cardiovascular drugs and therapies. The company’s current cardiovascular product portfolio comprises 1,250 products while 200 products are in the product pipeline, as shown in the chart above.
In August, Mylan launched the generic version of Eli Lilly’s (LLY) Adcirca, which is indicated for the treatment of pulmonary arterial hypertension for improving exercise ability. For more information on the drug, please read Mylan Launches First Adcirca Generic, Stock Moves Up. The launch occurred after the FDA’s approval of the drug, which was awarded marketing exclusivity for 180 days. The launch further strengthened Mylan’s cardiovascular portfolio.
Check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data, as well as dividend information. Take a look!